Todos os estudos
RecrutamentoFase I e Fase II (Integrado) - OutrosIntervencionista

An open label study followed by a randomised, double-blind, placebo-controlled, parallel group and an extension study to investigate the safety and efficacy of GB1211 (a galectin-3 inhibitor) in combination with atezolizumab in patients with Non-Small Cell Lung Cancer (NSCLC).

This research study is investigating a new treatment approach for people with non-small cell lung cancer. It combines an experimental drug called GB1211, which is a 'galectin-3 inhibitor', with an approved cancer drug called atezolizumab (also known as Tecentriq). The main goals are to understand how safe this new combination is and how effectively it can help control the cancer, such as shrinking tumours or preventing their growth. Various parts of the study will help researchers find the best dose of GB1211 and check for any side effects. Participants will be closely monitored, and some may receive a placebo alongside atezolizumab, while others get the active GB1211. This helps scientists compare the new treatment's effects clearly.

Em resumo

Status
Recrutamento
Fase
Fase I e Fase II (Integrado) - Outros
Patrocinador
Galecto Biotech AB
Meta de inscrição
49
Iniciar
04 Nov 2024

Sobre o que é este estudo?

This study is designed for individuals living with non-small cell lung cancer and is exploring a new combination treatment. It involves two medicines: GB1211, which is an investigational drug that works by blocking something called galectin-3, and atezolizumab (known as Tecentriq), which is an approved cancer treatment. Scientists believe that combining these two drugs might offer a more effective way to fight lung cancer.

The study has different stages, often called 'phases'. Initially, researchers are carefully looking at the safety of GB1211 when given with atezolizumab. They want to find the right dose that has good effects with manageable side effects. Once a safe dose is established, they will compare this new combination directly against atezolizumab given with a dummy pill (placebo). This helps them understand if adding GB1211 genuinely improves treatment outcomes, such as how much tumours shrink or if the cancer stops growing.

The main aim is to see if this new combination improves how long patients' cancer is controlled and if tumours respond well to the treatment. Researchers will also be tracking any side effects carefully. This type of study is crucial for discovering new and potentially better ways to treat serious conditions like lung cancer.

Pontos principais

  • This study evaluates a new drug (GB1211) combined with an approved treatment (atezolizumab) for lung cancer.
  • It aims to find a safe dose and see how well this combination works.
  • Participation involves receiving medication, regular check-ups, blood tests, and scans.
  • Some participants will receive a placebo to help compare the new treatment's effectiveness.
  • Sua saúde será monitorada de perto durante todo o estudo.
  • You can withdraw from the study at any time without affecting your medical care.

Quem pode ser elegível?

To be considered for this study, you must be at least 18 years old. The study is open to both men and women.

There might be other specific health requirements or conditions that would mean you can or cannot take part. These details are important to ensure the study is safe for you and that the results are clear. Your doctor will be able to discuss these with you.

It's important to remember that joining a clinical study is a big decision, and it’s always best to talk it through with your own doctor. They can help you understand if this particular study is a good fit for your health situation.

Este estudo pode ser adequado para você?

Responda a estas perguntas rápidas para ver se você pode ser elegível. Este é apenas um guia — a decisão final é da equipe de pesquisa.

  1. Você tem 18 anos ou mais?
  2. Do you have non-small cell lung cancer?
  3. Are you able to attend regular hospital appointments and tests?
  4. Are you currently receiving treatment or considering treatment for lung cancer?
Responda a todas as perguntas para ver o seu resultado.

O que envolve a participação?

If you join this study, you'll be monitored very closely by a medical team. You'll receive either the study drug GB1211 combined with atezolizumab, or a placebo (a dummy pill with no active drug) along with atezolizumab. The atezolizumab is given as an infusion, typically into a vein, and the GB1211 (or placebo) is likely given as capsules.

Throughout the study, you'll have regular hospital visits for health check-ups, blood tests, and scans (like X-rays or CT scans) to see how your body is responding to the treatment and how your cancer is behaving. These visits help the doctors track any side effects and see if the treatment is working. The total duration of your participation could vary, but follow-up is an important part of understanding the long-term effects.

Riscos e benefícios potenciais

Participation in any clinical study has potential benefits and potential risks. You might benefit from a new treatment that isn't widely available, and your health will be closely monitored by specialists. However, it's also possible that the new drug might not help your cancer, or you could experience side effects that might be mild, serious, or unexpected. You have the right to withdraw from the study at any time, for any reason, without it affecting your usual medical care.

Localizações (2)

Algumas localizações dos sites são aproximadas. Estamos melhorando isso — por favor, verifique com a equipe de teste antes de viajar.
  • —
    Não verificado
    França
  • —
    Não verificado
    Espanha

Perguntas frequentes

What is non-small cell lung cancer (NSCLC)?

NSCLC is a common type of lung cancer. This study is looking for new ways to treat it.

What is GB1211?

GB1211 is a new experimental drug that aims to block a protein called galectin-3, which might help fight cancer.

What is atezolizumab (Tecentriq)?

Atezolizumab is an existing approved cancer medicine that helps your body’s immune system fight cancer cells.

O que significa 'controlado por placebo'?

It means some people will get the active study drug, and others will get an inactive dummy pill (placebo) alongside their usual treatment to compare effects clearly.

Saberei se estou recebendo o novo medicamento ou o placebo?

No, in a 'double-blind' study, neither you nor your study doctors will know who is getting the active drug or the placebo. This helps prevent bias.

Como saber mais

Sempre consulte seu médico ou especialista antes de decidir participar de um estudo.

Interessado em participar?

Registre seu interesse

Compartilhe seus detalhes e a equipe de pesquisa para "An open label study followed by a randomised, double-blind, …" entrará em contato com você se você for elegível. Sempre fale com seu médico antes de concordar em participar.

Discussão

Discussão da comunidade

Desenvolvido pelo nosso fórum em community.patient.info. Por favor, seja respeitoso — isto não é um conselho médico.